Team examines use of antiparasitic drug as new treatment for brain tumors

April 11, 2017, Northwell Health
Marc Symons, PhD, professor at the Feinstein Institute for Medical Research is examining if a common medication administered to treat pinworms, could replace the current treatment used for certain brain cancers. Credit: Northwell Health

Marc Symons, PhD, professor in The Feinstein Institute for Medical Research's Karches Center for Oncology Research, is examining if a common medication administered to treat pinworms, could replace the current treatment used for certain brain cancers. These findings, which are published today in the Feinstein Institute Press's peer-reviewed, open-access journal Molecular Medicine, could help to extend the lives of patients suffering from one of the most common types of brain tumors—low-grade glioma.

Low-grade is a tumor that originates from cells that support and protect the brain's nervous system. Treatments for these tumors include surgery, radiotherapy and chemotherapy. Brain tumor chemotherapy is challenging as most drugs cannot penetrate the , a natural defense mechanism that prevents substances in the bloodstream from getting into the brain. For example, vincristine is a drug that is routinely used as part of different drug cocktails for the of , even though it is rather toxic and very poorly crosses the blood-brain barrier.

Dr. Symons and colleagues examined mebendazole, a medication that is used to treat parasitic pinworms and that in previous studies had been found to be effective in the treatment of glioma tumors. By studying how mebendazole kills isolated tumor cells in the laboratory, they showed that it works in exactly the same way as vincristine. They also found however, that while mebendazole effectively slowed down the growth of glioma tumors, vincristine did not work at all.

"We were rather surprised to see that vincristine, which is currently used to treat a range of different brain tumors, was totally ineffective in our in vivo glioma model," said Dr. Symons. "In contrast, in the same model, mebendazole performed quite well, most likely because mebendazole crosses the blood-brain barrier and reaches the much better than vincristine. The reason that vincristine may be erroneously believed to be effective for the treatment of brain tumors is that it always has been used in combination with other treatments."

Based on the new results— and due to the fact that vincristine often has severe side effects in comparison to relatively mild reactions to mebendzole—Dr. Symons and his team are now strongly motivated to initiate clinical trials to test whether vincristine can be exchanged by mebendazole in the treatment of brain tumors.

"Sometimes innovation can be looking at an existing treatment in a new light," said Kevin J. Tracey, MD, president and CEO of the Feinstein Institute. "This new approach needs to be tested in clinical trials, but with Dr. Symons' new findings we may be closer to a new treatment option that could prolong the lives of the patients suffering from low-grade glioma and other tumors."

Explore further: Genetic mutations help brain tumors evade targeting by immunotherapy treatments

More information: Molecular Medicine, static.smallworldlabs.com/molm … re/17_011_DeWitt.pdf

Related Stories

Genetic mutations help brain tumors evade targeting by immunotherapy treatments

March 20, 2017
Tumors of the brain and spinal cord, or gliomas, are among the most commonly occurring brain tumors. Although a majority of gliomas are classified as curable, these low-grade tumors have the potential to develop more aggressive ...

Neuroscientists pinpoint key gene controlling tumor growth in brain cancers

March 9, 2017
Cedars-Sinai investigators have identified a stem cell-regulating gene that affects tumor growth in patients with brain cancer and can strongly influence survival rates of patients. The findings, published in the online edition ...

New genetic risk factors identify two distinct glioma subtypes

March 27, 2017
An international consortium of researchers led by Dr. Melissa Bondy, professor of medicine, associate director for population sciences at the Dan L Duncan Comprehensive Cancer Center and McNair Scholar at Baylor College of ...

Researchers make breakthrough on immune system and brain tumors

September 27, 2012
In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different ...

Study reveals new information on how brain cancer spreads

November 17, 2016
Glioblastoma multiforme remains the most common and highly lethal brain cancer and is known for its ability to relapse. Researchers at The University of Texas MD Anderson Cancer Center have identified a pathway by which cancer ...

Recommended for you

Scientists create better laboratory tools to study cancer's spread

April 23, 2018
Cancer that has spread, or metastasized, from its original site to other tissues and organs in the body is a leading cause of cancer death. Unfortunately, research focused on metastatic disease has been limited by a lack ...

The role of 'extra' DNA in cancer evolution and therapy resistance

April 23, 2018
Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent. Research is beginning to provide a better understanding ...

Vitamin A derivative selectively kills liver cancer stem cells

April 23, 2018
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer. Now, in research published in Proceedings ...

Size, structure help poziotinib pose threat to deadly exon 20 lung cancer

April 23, 2018
A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer ...

How to hijack degrading complexes to put cancer cells asleep

April 23, 2018
Newcastle and Dundee University researchers have uncovered an alternative path of how the breast cancer drug palbociclib drives malignant cells into cell death, senescence.

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.